LCTX (STOCKS)
Lineage Cell Therapeutics, Inc.
$1.510000
+0.030000 (+2.03%)
Prev close: $1.480000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Brian M. Culley
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $374.88M
- Employees
- 77
- P/E (TTM)
- -5.42
- P/B (TTM)
- 8.24
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.00 | $-0.05 | +0.0527 | +100.00% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.03 | -0.1038 | -396.18% |
|
Jun 2025 (Q2)
|
$-0.07 | $-0.03 | -0.0423 | -152.71% |
|
Mar 2025 (Q1)
|
$-0.02 | $-0.03 | +0.0055 | +21.57% |
Financial Statements
| Revenues | $14.56M |
| Benefits Costs and Expenses | $83.20M |
| Costs And Expenses | $51.18M |
| Nonoperating Income/Loss | -$32.03M |
| Operating Expenses | $51.18M |
| Depreciation and Amortization | $699.00K |
| Research and Development | $17.73M |
| Other Operating Expenses | $32.75M |
| Operating Income/Loss | -$36.62M |
| Income/Loss From Continuing Operations After Tax | -$63.37M |
| Income/Loss From Continuing Operations Before Tax | -$68.65M |
| Income Tax Expense/Benefit | -$5.28M |
| Income Tax Expense/Benefit, Deferred | -$5.28M |
| Net Income/Loss | -$63.37M |
| Net Income/Loss Attributable To Noncontrolling Interest | $166.00K |
| Net Income/Loss Attributable To Parent | -$63.53M |
| Net Income/Loss Available To Common Stockholders, Basic | -$63.53M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.28 |
| Diluted Earnings Per Share | -$0.28 |
| Basic Average Shares | 230,116,000 |
| Diluted Average Shares | 230,116,000 |
| Assets | $112.58M |
| Current Assets | $59.16M |
| Noncurrent Assets | $53.43M |
| Fixed Assets | $2.57M |
| Intangible Assets | $31.70M |
| Other Non-current Assets | $19.16M |
| Liabilities | $69.24M |
| Current Liabilities | $11.37M |
| Accounts Payable | $2.34M |
| Wages | $3.74M |
| Other Current Liabilities | $5.28M |
| Noncurrent Liabilities | $57.87M |
| Equity | $43.35M |
| Equity Attributable To Noncontrolling Interest | -$1.20M |
| Equity Attributable To Parent | $44.55M |
| Liabilities And Equity | $112.58M |
| Net Cash Flow From Operating Activities | -$18.92M |
| Net Cash Flow From Operating Activities, Continuing | -$18.92M |
| Net Cash Flow From Investing Activities | -$13.46M |
| Net Cash Flow From Investing Activities, Continuing | -$13.46M |
| Net Cash Flow From Financing Activities | $26.95M |
| Net Cash Flow From Financing Activities, Continuing | $26.95M |
| Exchange Gains/Losses | $396.00K |
| Net Cash Flow | -$5.03M |
| Net Cash Flow, Continuing | -$5.43M |
| Comprehensive Income/Loss | -$64.41M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $166.00K |
| Comprehensive Income/Loss Attributable To Parent | -$64.58M |
| Other Comprehensive Income/Loss | -$1.04M |